Original Text: |
    FOR DOSE ESCALATION COHORTS ONLY: Pathologically confirmed breast cancer with the following features:
    * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
    * Estrogen receptor (ER) and progesterone receptor (PR) =< 1% by immunohistochemistry
    * Her-2/neu negative (0 or 1+ by immunohistochemistry OR not amplified by College of American Pathologists/American Society of Clinical Oncology [CAP/ASCO] standards)
    * Metastatic or unresectable and locally advanced and not amenable to treatment with curative intent, in the opinion of the enrolling investigator OR
    * Platinum-resistant (defined as progression within 12 months of last platinum therapy administration), pathologically confirmed serous ovarian cancer that is recurrent and unresectable, in the opinion of the enrolling investigator
Disease/Condition: Breast Cancer
Procedure: none
Drug: none
Biomarker: ER-, PR-, Her-2/neu-
Computable Rule: |
    Disease is "Breast Cancer" AND ER is False AND PR is False AND Her-2/neu is False
